Raytheon awarded $71 million in Navy contracts for missile systems
LONDON - Verici Dx plc (AIM:VRCI), a company specializing in advanced clinical diagnostics for organ transplant, has announced its intention to seek shareholder approval for the issuance of new Ordinary Shares. The general meeting is scheduled for May 27, 2025, at the offices of Shoosmiths LLP in London.
The decision to issue new shares follows the company’s announcement on April 7, 2025, regarding a fundraising initiative aimed at accelerating commercial growth and augmenting Tutivia™ revenues. Verici Dx has recently secured Medicare Coverage for Tutivia™, as disclosed on April 10, 2025, and the additional funds will support the company’s commercial objectives and extend its cash runway.
The company’s current allotment authorities from the last annual general meeting are not sufficient for the proposed fundraising. Therefore, Verici Dx is seeking further authority to issue and allot new Ordinary Shares on a non-pre-emptive basis during the upcoming general meeting.
Details regarding the size and structure of the fundraising are still under consideration by the board, with plans to include a placement with institutional and other investors. The company, along with its advisers, is determining the optimal size, structure, and timing for the fundraising, and will provide updates as appropriate.
Shareholders will receive the Circular and notices of its availability on the company’s website, which will also host these documents for public access. The information for the proposed share issuance is based on a press release statement from Verici Dx plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.